Literature DB >> 31426692

Assessing Patient Participation Burden Based on Protocol Design Characteristics.

Kenneth Getz1, Venkat Sethuraman2, Jessica Rine2, Yaritza Peña1, Sharma Ramanathan2, Stella Stergiopoulos1.   

Abstract

BACKGROUND: Although a number of studies have quantitatively measured investigative site burden to administer increasingly complex protocol designs, robust scholarly research has not been performed to quantify the burden that patients face as participants in clinical trials.
METHODS: This paper presents the results of a cross-sectional pilot study conducted by the Tufts Center for the Study of Drug Development and ZS Associates among nearly 600 patients via an online survey conducted between February and March 2019. Respondents rated the perceived burden of 60 commonly administered protocol procedures. The association and relationship between overall patient burden-derived from aggregating mean perceived burden ratings for individual procedures-and performance (eg, screen failure and retention rates, clinical trial cycle times) for a cross-sectional sample of 137 individual protocols was assessed. Descriptive statistics, significance tests, and univariate analyses were performed.
RESULTS: Strong positive, statistically significant associations were observed between a composite measure of patient burden and protocol-specific design and performance measures, most notably study visits above the tolerable mean and the study conduct duration from first patient first visit to last patient last visit.
CONCLUSIONS: The study results suggest a new and viable approach to optimize protocol design and improve patient engagement.

Entities:  

Keywords:  patient participation burden; protocol design complexity; protocol design optimization; study volunteer burden

Year:  2019        PMID: 31426692     DOI: 10.1177/2168479019867284

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  4 in total

Review 1.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

2.  Health Communication and Decision Making about Vaccine Clinical Trials during a Pandemic.

Authors:  Aisha T Langford
Journal:  J Health Commun       Date:  2020-10-02

Review 3.  Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion.

Authors:  Noah Goodson; Paul Wicks; Jayne Morgan; Leen Hashem; Sinéad Callinan; John Reites
Journal:  NPJ Digit Med       Date:  2022-05-05

4.  Stakeholders' views on drug development: the congenital disorders of glycosylation community perspective.

Authors:  Maria Monticelli; Rita Francisco; Sandra Brasil; Dorinda Marques-da-Silva; Tatiana Rijoff; Carlota Pascoal; Jaak Jaeken; Paula A Videira; Vanessa Dos Reis Ferreira
Journal:  Orphanet J Rare Dis       Date:  2022-07-30       Impact factor: 4.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.